Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

Por Crooke, Stanley T, Geary, Richard S
Publicado em 2013

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Por Geary, Richard S., Baker, Brenda F., Crooke, Stanley T.
Publicado no Clin Pharmacokinet (2015)

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications

Por Yu, Rosie Z, Grundy, John S, Henry, Scott P, Kim, Tae-Won, Norris, Daniel A, Burkey, Jennifer, Wang, Yanfeng, Vick, Andrew, Geary, Richard S
Publicado no Mol Ther Nucleic Acids (2015)

Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice

Por Yu, Rosie Z, Graham, Mark J, Post, Noah, Riney, Stan, Zanardi, Thomas, Hall, Shannon, Burkey, Jennifer, Shemesh, Colby S, Prakash, Thazha P, Seth, Punit P, Swayze, Eric E, Geary, Richard S, Wang, Yanfeng, Henry, Scott
Publicado no Mol Ther Nucleic Acids (2016)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers

Por Crooke, Stanley T, Baker, Brenda F, Kwoh, T Jesse, Cheng, Wei, Schulz, Dan J, Xia, Shuting, Salgado, Nelson, Bui, Huynh-Hoa, Hart, Christopher E, Burel, Sebastien A, Younis, Husam S, Geary, Richard S, Henry, Scott P, Bhanot, Sanjay
Publicado no Mol Ther (2016)

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-control...

Por Visser, Maartje E., Wagener, Gilbert, Baker, Brenda F., Geary, Richard S., Donovan, Joanne M., Beuers, Ulrich H.W., Nederveen, Aart J., Verheij, Joanne, Trip, Mieke D., Basart, Dick C.G., Kastelein, John J.P., Stroes, Erik S.G.
Publicado em 2012